EPISODE · Jan 16, 2019 · 15 MIN
Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders
from RARECast
Tiburio Therapeutics emerged from the orphan drug accelerator Cydan at the start of 2019. The company is developing two clinical stage compounds for rare endocrine disorders that it licensed from Ipsen. We spoke to Tiburio Therapeutics CEO Abraham Ceesay, about rare endocrine disorders, the company’s pipeline, and the case for Cydan’s business model.
Embed this episode
NOW PLAYING
Orphan Drug Accelerator Spin-Out Tackles Rare Endocrine Disorders
0:00
15:59
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of RARECast?
This episode is 15 minutes long.
When was this RARECast episode published?
This episode was published on January 16, 2019.
Can I download this RARECast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!